

Bioheaven360 introduces Al-driven genomics diagnostic platform for early disease detection

09 May 2025 | News

Developed through rigorous research and clinical trials in collaboration with AIIMS



Bioheaven360 Genotec, a leading Delhi-based biotechnology startup, has has introduced its cutting-edge Al-powered genomics diagnostics platform in the Indian market. Designed to enable early disease detection and personalised treatment plans, the platform marks a significant shift from reactive to proactive healthcare.

The platform has been developed through rigorous research and clinical trials in collaboration with the All India Institute of Medical Sciences (AIIMS), New Delhi. It integrates deep phenotyping to capture comprehensive patient data from multiple sources including genetic information, lifestyle factors, biomarkers, and environmental influences. Through this, the platform generates highly accurate cumulative risk assessments that can identify disease predispositions decades before symptoms appear.

Commenting on the same, Dr Shailendra Vyas, Founder and CEO of Bioheaven360 Genotec, shared, "Our platform aims to revolutionise preventive healthcare by providing personalized recommendations to mitigate risks and improve overall health outcomes. With our cutting-edge technology, we strive to empower individuals to take proactive steps towards a healthier future. By leveraging the latest advancements in genetic testing and data analysis, our platform offers a comprehensive approach to preventive healthcare that goes beyond traditional methods. Our goal is to empower individuals with the knowledge and tools they need to make informed decisions about their health and well-being."

The platform leverages advanced machine learning algorithms that continuously refine in real-time, enhancing diagnostic precision with every new dataset. It includes extensive phenotyping that captures patient data from various sources, cumulative risk assessments, Al-powered diagnostic support, and self-learning capabilities.

Initially designed for the early detection of osteoporosis, the platform's applications will soon broaden to encompass a wider range of chronic and complex conditions. It is engineered to rapidly analyse intricate medical datasets including genomic sequences, imaging results, and biomarker profiles delivering insights far faster and more accurately than conventional diagnostic tools.